Sol-Gel Technologies Ltd. — FY2021 Form 20-F
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone Q4 filing; the supplied filing text does not provide quarterly financial results. Financial statements are prepared under U.S. GAAP and audited.
Business context
Sol-Gel is an Israel-based dermatology company developing topical prescription and generic products using a silica-based microencapsulation platform. Twyneo, for acne, received FDA approval in July 2021. Epsolay, for papulopustular rosacea, remained under FDA review at year-end. U.S. commercialization of both products is licensed to Galderma; the company reported limited in-house sales and marketing capabilities.
Key financial metrics
| Metric (US$ millions, except per-share data) | FY2021 | FY2020 |
|---|---|---|
| Total revenue | 31.3 | 8.8 |
| Operating income (loss) | 3.0 | (30.2) |
| Net income (loss) | 3.2 | (29.3) |
| Basic and diluted earnings (loss) per share | $0.14 | $(1.30) |
| Research and development expense | 20.4 | 27.9 |
| General and administrative expense | 8.5 | 11.1 |
| Net cash used in operating activities | (7.7) | (25.2) |
| Cash, bank deposits and marketable securities at year-end | 43.2 | 50.2 |
| Total assets / total liabilities at year-end | 69.2 / 13.6 | 59.2 / 8.3 |
Revenue increased about 257% year over year. Operating and net margins were approximately 9.5% and 10.3%, respectively; no gross-margin figure is presented. Year-end current assets were $57.1 million and current liabilities $11.7 million. The filing reports no significant long-term borrowings; liabilities primarily include payables, employee obligations and operating lease liabilities. Operating cash flow remained negative despite the reported profit.
Material changes versus FY2020
- Revenue rose from $8.8 million to $31.3 million, including $20.4 million recognized from the sale of rights to ten generic collaboration programs to Padagis, $3.3 million of generic collaboration revenue, and $7.5 million of Galderma license revenue.
- Net income swung to $3.2 million from a $29.3 million loss. The result included a $20.4 million R&D reduction and a $2.6 million reduction in G&A; R&D decline primarily reflected completion of Twyneo and Epsolay clinical trials.
- Operating cash outflow narrowed by $17.6 million. The company attributed FY2021 cash use in part to a $12.5 million net working-capital outflow, including increased collaboration receivables.
- Cash, deposits and marketable securities declined by approximately $7.0 million. Financing cash inflow was $0.8 million, versus $26.5 million in 2020, when the company completed equity offerings.
Outlook, risks and unusual items
- Management estimated existing resources would fund operating expenses and capital needs at least through the end of 2023, assuming timely Epsolay approval. The financial-statement note separately states resources were expected to fund the operating plan for at least 12 months from issuance. Both estimates depend on assumptions; management said additional financing may be needed.
- Twyneo U.S. launch was anticipated in spring 2022, with Galderma responsible for U.S. commercial activities. Revenue depends in part on partner execution, product uptake and royalties or milestones under the license agreements.
- Epsolay approval was pending at year-end. Its FDA review had been delayed in connection with COVID-19-related inspection restrictions, and the FDA conducted a pre-approval manufacturing-site inspection in February 2022. Galderma could terminate the Epsolay license if approval was not obtained by March 31, 2022. The filing states the $4 million Epsolay upfront payment was refundable if approval was not received by December 31, 2021; it was recorded as a liability and refunded in March 2022.
- The Padagis agreement provides $21.5 million over 24 months in exchange for rights to ten generic programs and ends Sol-Gel’s related operating-cost obligations. The filing describes the amount as unconditional; verify collection timing and remaining receivables.
- Major risks include ongoing cash burn and potential need for capital, regulatory and clinical uncertainty, reliance on Galderma and other third parties, manufacturing and supply constraints, competition, reimbursement and pricing pressures, and COVID-19 disruption. The company also disclosed currency exposure, Israeli operating risks, and uncertainty around its U.S. PFIC tax status.
- The company reported no material legal proceedings. Management concluded internal control over financial reporting was effective at December 31, 2021; the independent auditor did not attest to that assessment.
Most important facts for investors to verify
- Subsequent FDA and commercial status of Epsolay, and any effect on Galderma’s license, milestones or royalties.
- Whether the stated cash runway assumptions remain valid after the $4 million Galderma refund, ongoing operating cash use and collection of Padagis installments and collaboration receivables.
- Actual Twyneo launch performance, sales, net-sales royalties, milestones and commercial uptake.
- How much FY2021 profit reflects recurring collaboration or product economics versus the one-time Padagis rights transaction and license-related revenue.
- Potential dilution from the $25 million ATM facility; the filing reports approximately $0.5 million of gross sales through its issuance date and about $24.5 million remaining.